- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02476058
A Safety, Efficacy and Biomarker Study of JNJ-42847922 in Participants With Major Depressive Disorder
January 3, 2023 updated by: Janssen-Cilag International NV
An Exploratory Multicenter, Double-Blind, Diphenhydramine- and Placebo-Controlled Safety, Efficacy and Biomarker Study With JNJ-42847922 in Subjects With Major Depressive Disorder
The purpose of this study is to evaluate the safety and tolerability of JNJ-42847922 in participants with Major Depressive Disorder (MDD).
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This will be a multi-center (when more than one hospital works on a medical research study), randomized (study medication assigned to participants by chance), double-blind (neither the researchers nor the participants know what treatment the participant is receiving) and placebo-controlled (an inactive substance; a pretend treatment [with no drug in it] that is compared in a clinical trial with a drug to test if the drug has a real effect) study.
This study will consist of an eligibility screening examination (between 28 days and 1 day prior to the first dose administration), a parallel group treatment phase of 10 days or 4 weeks, and a follow-up period of 2 weeks including 2 follow-up visits.
The duration of study will be 12 months.
Participants will be randomly assigned to receive either JNJ-42847922, Diphenhydramine or Placebo.
Participants' safety will be monitored throughout the study.
Study Type
Interventional
Enrollment (Actual)
48
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Aalst, Belgium
-
Brussel, Belgium
-
Duffel, Belgium
-
-
-
-
-
Berlin, Germany
-
Hamburg, Germany
-
Schwerin, Germany
-
-
-
-
-
Leiden, Netherlands
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 64 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Before randomization, a woman must be either: 1) Not of childbearing potential: postmenopausal; permanently sterilized; or otherwise be incapable of pregnancy. 2) Of childbearing potential and practicing a highly effective method of birth control consistent with local regulations regarding the use of birth control methods for participants participating in clinical studies: example, established use of oral, injected or implanted hormonal methods of contraception; placement of an intrauterine device (IUD) or intrauterine system (IUS) in combination with barrier methods: condom with spermicidal foam/gel/film/cream/suppository or occlusive cap with spermicidal foam/gel/film/cream/suppository; male partner sterilization; true abstinence. Women must agree to continue using these methods of contraception throughout the study and for at least 3 months after receiving the last dose of study medication
- Participant Body mass index (BMI) must be between 18 and 30 kilogram per square meter (kg/m2) inclusive
- Participant must meet the Diagnostic and Statistical Manual of Mental Disorders-IV (DSM-IV) or 5 diagnostic criteria for major depressive disorder (MDD) without psychotic features, and confirmed by the Mini International Neuropsychiatric Interview (MINI) 6.0; Participant must have an Inventory of Depressive Symptomatology- Clinician rated-30 (IDS-C30) total score greater than or equal to (>=) 30; Participant is either currently antidepressant naive or currently being treated with a maximum of two concurrent antidepressants. If the subject is currently treated with antidepressants, they have to be given at an optimal dose and for at least 4 weeks, but not longer than 24 weeks with a suboptimal response
- A man who is sexually active with a woman of childbearing potential and has not had a vasectomy must agree to use a barrier method of birth control e.g., either condom with spermicidal foam/gel/film/cream/suppository or partner with occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository, and all men must also not donate sperm during the study and for 3 months after receiving the last dose of study drug
- Participant must be willing and able to adhere to the prohibitions and restrictions specified in this protocol
Exclusion Criteria:
- Women who is pregnant or breast feeding
- Participant has a history of malignancy within 5 years before screening (exceptions are squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix, or malignancy that in the opinion of the investigator, with concurrence with the sponsor's study responsible physician, is considered cured with minimal risk of recurrence)
- Participant has a primary DSM diagnosis of general anxiety disorder (GAD), panic disorder, obsessive compulsive disorder (OCD), posttraumatic stress disorder (PTSD), anorexia nervosa, or bulimia nervosa. Subjects with comorbid GAD, social anxiety disorder (SAD), or panic disorder for whom MDD is considered the primary diagnosis are not excluded
- Participant has a length of current major depressive episode (MDE) >24 months despite adequate treatment
- Participant has failed more than 2 treatments with a different pharmacological mode of action despite an adequate dose and duration during a previous, or the current depressive episode
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: JNJ-42847922
JNJ-428479, 20 milligram (mg) capsule, orally, once daily, at bedtime for 10 days in women of childbearing potential (WOCBP) or for 4 weeks in all other participants.
|
JNJ-428479, 20 milligram (mg) capsule, orally, once daily, at bedtime for 10 days in women of childbearing potential (WOCBP) or for 4 weeks in all other participants.
|
Experimental: Diphenhydramine
Diphenhydramine 25 mg capsule, orally, once daily, at bedtime for 10 days in women of childbearing potential (WOCBP) or for 4 weeks in all other participants.
|
Diphenhydramine 25 mg capsule, orally, once daily, at bedtime for 10 days in women of childbearing potential (WOCBP) or for 4 weeks in all other participants.
|
Placebo Comparator: Placebo
Matching placebo (capsules containing neutral pellets), orally, once daily, at bedtime for 10 days in women of childbearing potential (WOCBP) or for 4 weeks in all other participants.
|
Matching placebo (capsules containing neutral pellets), orally, once daily, at bedtime for 10 days in women of childbearing potential (WOCBP) or for 4 weeks in all other participants.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Adverse Events (AEs) or Serious Adverse Events (SAEs)
Time Frame: Screening until follow-up phase (up to 12 months)
|
An AE is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.
An SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; lifethreatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
|
Screening until follow-up phase (up to 12 months)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Participants Leeds Sleep Evaluation Questionnaire (LSEQ) Score
Time Frame: Day 2, 11, 29, 31, 42
|
The LSEQ comprises 10 self-rating 100 millimeter (mm)-line analogue questions regarding changes in the quality of sleep and early morning behavior, following any given intervention.
Scores range between 0 and 100.
Scores beneath 50 indicate better sleep.
|
Day 2, 11, 29, 31, 42
|
Computerized Cognitive Test Battery: ISLT (Verbal Learning and Memory) Test
Time Frame: Day 1, 2 , 5, 6, 10 and 11
|
The ISLT is a measure of verbal learning and memory and uses a well-validated list-learning paradigm.
The task is administered using a computer.
High frequencies, high imagery, concrete nouns (items from a shopping list) are read to the participant by the test supervisor at the rate of one word every two seconds.
Once the [12] words have been read, the participant is asked to recall as many of the words as he/she can as quickly as possible.
The test supervisor uses a mouse or stylus to mark the words recalled by the participant on the computer screen.
When the participant can recall no more words, the same list is read a second time.
The test supervisor records the words recalled by the participant on this trial.
This is then repeated a third time.
The delayed recall condition requires the participant to recall the words from the list after a delay without having the list read again.
|
Day 1, 2 , 5, 6, 10 and 11
|
Computerized Cognitive Test Battery: Detection (DET) Test
Time Frame: Day 1, 2 , 5, 6, 10 and 11
|
Simple reaction time task measuring processing speed; mean of the log10 transformed reaction times for correct responses (lower score = better performance).
|
Day 1, 2 , 5, 6, 10 and 11
|
Computerized Cognitive Test Battery: Identification (IDN) Test
Time Frame: Day 1, 2 , 5, 6, 10 and 11
|
Choice reaction time paradigm measuring attention; mean of the log10 transformed reaction times for correct responses (lower score = better performance).
|
Day 1, 2 , 5, 6, 10 and 11
|
Computerized Cognitive Test Battery: One Back (OBK) Test
Time Frame: Day 1, 2 , 5, 6, 10 and 11
|
Working memory measure; mean of the log10 transformed reaction times for correct responses (lower score = better performance).
|
Day 1, 2 , 5, 6, 10 and 11
|
Computerized Cognitive Test Battery: Groton Maze Learning Test (GMLT)
Time Frame: Day 1, 2 , 5, 6, 10 and 11
|
Executive function measure; total number of errors made in attempting to learn the same hidden pathway on five consecutive trials during a single session (lower score = better performance).
|
Day 1, 2 , 5, 6, 10 and 11
|
Polysomnography (PSG) Objective Assessment of Latency To Persistent Sleep
Time Frame: Day 1 to 2, 5 to 6 and 10 to 11
|
Objective assessment: A central scoring facility was used to derive the PSG sleep parameters Latency to Persistent Sleep (LPS) from the epochs and stages collected via the polysomnography (PSG) recordings.
Each epoch is 30 seconds.
Latency to persistent sleep (LPS; minutes): time from lights out to the first of 20 consecutive epochs (10 minutes) of non-wake, as determined by PSG recordings.
|
Day 1 to 2, 5 to 6 and 10 to 11
|
Subjective Assessment of Latency To Persistent Sleep
Time Frame: Women of childbearing potential (WOCBP): Day 2, 11 and follow up visit (Day 13 and 24); Males and women of non-childbearing potential (WONCBP): Day 2, 11, 29 and follow up visit (Day 31 and 42)
|
Subjective assessment: The amount of time measured in minutes it takes to fall asleep was based on participant-reported subjective assessments of sleep disturbance and was obtained from participants' responses to morning questionnaires.
|
Women of childbearing potential (WOCBP): Day 2, 11 and follow up visit (Day 13 and 24); Males and women of non-childbearing potential (WONCBP): Day 2, 11, 29 and follow up visit (Day 31 and 42)
|
PSG Objective Assessment of Total Sleep Time
Time Frame: Day 1 to 2, 5 to 6 and 10 to 11
|
Objective assessment: A central scoring facility was used to derive the PSG sleep parameter of Total Sleep Time (TST) from the epochs and stages collected via the PSG recordings.
The PSG parameters provided an objective assessment of the subject's sleep on a given night.
Total sleep time was defined as the number of non-wake epochs from the beginning of recording to the end of recording divided by 2.
|
Day 1 to 2, 5 to 6 and 10 to 11
|
Subjective Assessment of Total Sleep Time
Time Frame: Women of childbearing potential (WOCBP): Day 2, 11 and follow up visit (Day 13 and 24); Males and women of non-childbearing potential (WONCBP): Day 2, 11, 29 and follow up visit (Day 31 and 42)
|
Subjective assessment: The subjective measure was based on participant-reported subjective assessments of sleep disturbance and were obtained from participants' responses to morning questionnaires.
|
Women of childbearing potential (WOCBP): Day 2, 11 and follow up visit (Day 13 and 24); Males and women of non-childbearing potential (WONCBP): Day 2, 11, 29 and follow up visit (Day 31 and 42)
|
PSG Objective Assessment of Wake Time After Sleep Onset (WASO)
Time Frame: Day 1 to 2, 5 to 6 and 10 to 11
|
Objective assessment: A central scoring facility was used to derive the PSG sleep parameters Wake Time After Sleep Onset (WASO) from the epochs and stages collected via the PSG recordings.
Each epoch is 30 seconds.
Wake time after sleep onset (WASO; minutes): The number of wake epochs after the onset of persistent sleep to the end of the recording, divided by 2.
|
Day 1 to 2, 5 to 6 and 10 to 11
|
Subjective Assessment of Wake Time After Sleep Onset (WASO)
Time Frame: Women of childbearing potential (WOCBP): Day 2, 11 and follow up visit (Day 13 and 24); Males and women of non-childbearing potential (WONCBP): Day 2, 11, 29 and follow up visit (Day 31 and 42)
|
Subjective assessment: The subjective measure was based on participant-reported subjective assessments and were obtained from participants' responses to morning questionnaires.
|
Women of childbearing potential (WOCBP): Day 2, 11 and follow up visit (Day 13 and 24); Males and women of non-childbearing potential (WONCBP): Day 2, 11, 29 and follow up visit (Day 31 and 42)
|
Inventory of Depressive Symptomatology-clinician Rated 30 (IDSC30) Score and Structured Interview Guide for Hamilton Depression Scale (SIGH-D) (as combined SIGHD-IDS)
Time Frame: Day 1, 11, 29, 31 and 42
|
The SIGHD-IDS is a combined structured interview guide to complete both the structured interview guide for the Hamilton Depression Scale (SIGH-D) and the Inventory of depressive symptomatology (IDS-C30).
The SIGH-D interview guide is based on the Hamilton Depression Rating Scale (HDRS17; Williams 1988).
It contains 17 items pertaining to symptoms of depression experienced over the past week.
Score range is from 0 to 52.
The IDS-C30 is a standardized 30 item, clinician rated, scale to assess the severity of a participant's depressive symptoms.
The scale uses the 9 symptom domains of the Diagnostic and Statistical Manual of Mental Disorders (DSM)-IV criteria to measure symptom severity.
The scores range from a minimum of 0 to a maximum score of 84.
The higher the score the more severe the symptoms of depression.
|
Day 1, 11, 29, 31 and 42
|
Quick Inventory of Depressive Symptoms-16 (QIDS-SR16) Score
Time Frame: Day 1, 11, 29, 31 and 42
|
The QIDS-SR16 is a participant reported measure designed to assess the severity of depressive symptoms.
Participants provide responses to each item of this instrument with a 4-point Likert scale, with scores ranging from 0-3 for each item.
The 7-day period prior to assessment is the usual recall period for assessing symptom severity.
The total score ranges from 0 to 27.
Using a scale of severity of depression of none, mild, moderate, severe, and very severe, corresponding QIDS-SR16 total scores are none 1-5, mild 6-10, moderate 11-15, severe 16-20 and very severe 21-27.
|
Day 1, 11, 29, 31 and 42
|
Ruminative Response Scale (RRS) Score
Time Frame: Day 1, 11 and 29
|
Ruminative Response Scale is used to assess symptoms of rumination.
It is a 22-item scale.
Each item ranges from 1= almost never to 4 = almost always.
Total score ranges from 1 to 4.
|
Day 1, 11 and 29
|
Changes in Major Depressive Disorder (MDD)-related Biomarkers
Time Frame: Day 1, 11 and 29
|
Different biomarkers in blood (Interleukin-6 [IL-6]) and saliva (cortisol) will be measured to explore a relation to the seriousness of depressive symptoms or exposure to JNJ-42847922.
|
Day 1, 11 and 29
|
Plasma concentrations for JNJ-42847922
Time Frame: Day 1, 2, 6, 11 and 29
|
Day 1, 2, 6, 11 and 29
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 11, 2015
Primary Completion (Actual)
January 4, 2016
Study Completion (Actual)
January 4, 2016
Study Registration Dates
First Submitted
May 29, 2015
First Submitted That Met QC Criteria
June 16, 2015
First Posted (Estimate)
June 19, 2015
Study Record Updates
Last Update Posted (Actual)
January 5, 2023
Last Update Submitted That Met QC Criteria
January 3, 2023
Last Verified
January 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Behavioral Symptoms
- Mental Disorders
- Pathologic Processes
- Mood Disorders
- Depression
- Depressive Disorder
- Disease
- Depressive Disorder, Major
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Autonomic Agents
- Peripheral Nervous System Agents
- Sensory System Agents
- Anesthetics
- Antiemetics
- Gastrointestinal Agents
- Dermatologic Agents
- Hypnotics and Sedatives
- Anesthetics, Local
- Anti-Allergic Agents
- Sleep Aids, Pharmaceutical
- Histamine H1 Antagonists
- Histamine Antagonists
- Histamine Agents
- Antipruritics
- Diphenhydramine
- Promethazine
Other Study ID Numbers
- CR107002
- 42847922MDD1001 (Other Identifier: Janssen-Cilag International NV)
- 2014-005182-75 (EudraCT Number)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Major Depressive Disorder
-
Shalvata Mental Health CenterUnknownMAjor Depressive DisorderIsrael
-
York UniversityCentre for Addiction and Mental HealthSuspendedDisorder, Major DepressiveCanada
-
Seasons Biotechnology (Taizhou) Co., Ltd.CompletedMajor Depressive Disorder (MDDIndia
-
Gangnam Severance HospitalCompletedMajor Depressive Disorder(MDD)Korea, Republic of
-
University College, LondonCompletedUnipolar Major Depressive DisorderUnited Kingdom
-
Fundació Institut de Recerca de l'Hospital de la...Fondo de Investigacion SanitariaUnknown
-
Seasons Biotechnology (Taizhou) Co., Ltd.CompletedMajor Depressive Disorder (MDD)India
-
Repurposed Therapeutics, Inc.Unknown
-
GlaxoSmithKlineCompletedMajor Depressive Disorder (MDD)United States
-
AccexibleRecruitingMajor Depressive Disorder (MDD)Spain
Clinical Trials on JNJ-42847922
-
Janssen-Cilag International NVCompleted
-
Janssen Research & Development, LLCCompleted
-
Janssen Pharmaceutical K.K.Completed
-
Janssen Research & Development, LLCCompletedHealthy | Hepatic ImpairmentGermany
-
Janssen Research & Development, LLCRecruitingRenal ImpairmentUnited States
-
Janssen Research & Development, LLCCompletedInsomniaGermany, United States, Netherlands
-
Janssen Research & Development, LLCCompleted
-
Janssen Research & Development, LLCCompleted
-
Janssen Research & Development, LLCCompletedDepressive Disorder, MajorBelgium, United Kingdom, Germany, United States, Netherlands
-
Janssen Research & Development, LLCRecruitingAlzheimer DiseaseUnited States